Lamotrigine Extended Release Tablets

Modification P00007 SPE2D220D0092 issued to invoke option year 4 for Lamotrigine ER National Contract. Modification P000006 SPE2D220D0092 to incorporate Drug Supply Chain Act (DSCA) into soliciation for subject contract. Modification P00005 SPE2D220D0092 to incorporate FAR 52.204-27 Prohibition on a Bytedance covered Application (June 2023) into contract. Modification P00004 SPE2D220D0092 issued to invoke option year 3 for Lamotrigine ER National Contract.

Modification P00003 SPE2D220D0092 issued to invoke option year 2 for Lamotrigine ER National Contract. Modification P00002 SPE2D220D0092 issued to invoke option year 1 for Lamotrigine ER National Contract. Modification P00001 SPE2D220D0092 is issued to incorporate FAR 52.204-24 and FAR 52.204-25 into subject solicitation.

Amendment 0003 SPE2D220R0059 dated 02/14/2020 is issued to change the closing date to reflect February 25,2020 at 3:00 PM EST.

Amendment 0002 SPE2D220R0059 dated 01/31/2020 is issued to correct the solicitation number on page four (4) of subject Request for Proposal Block 9: Submission Instructions to reflect Solicitation Number: SPE2D2-20-R-0059 I/L/L SPE2D2-19-R-0059.

Amendment 0001 SPE2D220R0059 dated 01/23/2020 issued to update the dates for FAR clauses 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment and 52.212-3, Offeror Representation and Certifications-Commercial Items; and to incorporate clause FAR.204-26 Covered Telecommunications Equipment or Services-Representation into the solicitation. Solicitation for Lamotrigine ER Tablets SPE2D220R0059.